TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35772258

Group type: EXPERIMENTAL
Intervention: Moderate internalizing and externalizing symptoms (with low alcohol misuse)
Number of subjects: 1689

Group type: EXPERIMENTAL
Intervention: Highest internalizing and externalizing symptoms (with highest social disconnection)
Number of subjects: 1689

Group type: EXPERIMENTAL
Intervention: Lowest internalizing symptoms and low externalizing (with highest social connection and alcohol misuse)
Number of subjects: 1689
Study: 35772392

Group type: EXPERIMENTAL
Intervention: High stress hyperglycemia ratio (SHR)
Number of subjects: 6892

Group type: EXPERIMENTAL
Intervention: Adding SHR to the original model
Number of subjects: 6892
Study: 35772417

Group type: EXPERIMENTAL
Intervention: Daily PrEP (tenofovir disoproxil 245 mg and emtricitabine 200 mg, one pill per day)
Number of subjects: 3065

Group type: EXPERIMENTAL
Intervention: On-demand PrEP (following IPERGAY dosing recommendation)
Number of subjects: 3065

Group type: COMPARATOR
Intervention: Daily PrEP
Number of subjects: 3065

Group type: COMPARATOR
Intervention: On-demand PrEP
Number of subjects: 3065
Study: 35772429

Group type: EXPERIMENTAL
Intervention: SHR2554 (350 mg twice daily)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: SHR2554 (various doses)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: SHR2554 (all doses)
Number of subjects: 113
Study: 35772805

Group type: EXPERIMENTAL
Intervention: Gadolinium administration (20 and 120 minutes)
Number of subjects: 95
Study: 35772833

Group type: EXPERIMENTAL
Intervention: Participants with moderate to severe ACE
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Long-term relapse assessment
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Short-term relapse assessment
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Task-based functional MRI (fMRI)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Saliva cortisol and blood samples
Number of subjects: 36
Study: 35772852

Group type: EXPERIMENTAL
Intervention: Intraventricular enzyme replacement therapy (ERT) with cerliponase alfa
Number of subjects: 28
Study: 35772853

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan 24/26 mg twice a day
Number of subjects: 445
Study: 35772855

Group type: EXPERIMENTAL
Intervention: Happy heart syndrome (pleasant emotional events)
Number of subjects: 910

Group type: COMPARATOR
Intervention: Broken heart syndrome (negative emotional events)
Number of subjects: 910
Study: 35772857

Group type: EXPERIMENTAL
Intervention: HM3 LVAD
Number of subjects: 485
Study: 35773299

Group type: EXPERIMENTAL
Intervention: Invasive ventilation in prone position
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation in prone position
Number of subjects: 28

Group type: COMPARATOR
Intervention: Supine position (control for invasive ventilation)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Supine position (control for non-invasive ventilation)
Number of subjects: 28
Study: 35773354

Group type: EXPERIMENTAL
Intervention: Long chewing time (brown rice: 41s/bite; chickpeas: 37s/bite)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Short chewing time (brown rice: 23s/bite; chickpeas: 20s/bite)
Number of subjects: 26
Study: 35773363

Group type: EXPERIMENTAL
Intervention: Andecaliximab (ADX) combined with S-1 plus cisplatin (SP)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Andecaliximab (ADX) combined with S-1 plus oxaliplatin (SOX)
Number of subjects: 16
Study: 35773640

Group type: EXPERIMENTAL
Intervention: Rehabilitation treatment
Number of subjects: 200
Study: 35773649

Group type: EXPERIMENTAL
Intervention: Normal gait group
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Abnormal gait group
Number of subjects: 1600
Study: 35774109

Group type: EXPERIMENTAL
Intervention: Serum, plasma, saliva, and cerebrospinal fluid (CSF) samples from 8 healthy volunteers
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Serum and CSF samples collected at 13 timepoints over a 24-h period after catheter placement from 7 healthy volunteers
Number of subjects: 15
Study: 35774470

Group type: EXPERIMENTAL
Intervention: Gut microbiome characteristics in lung cancer patients
Number of subjects: 61

Group type: COMPARATOR
Intervention: Healthy people (control group)
Number of subjects: 61
Study: 35774932

Group type: EXPERIMENTAL
Intervention: Community-based, respondent-driven sampling (RDS) survey with HCV screening and immediate treatment
Number of subjects: 554
Study: 35775211

Group type: EXPERIMENTAL
Intervention: Breast cancer therapy with physical activity (PA) participation
Number of subjects: 110

Group type: COMPARATOR
Intervention: Breast cancer therapy without physical activity (inactive)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Pre-treatment physical activity scores
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Post-treatment physical activity scores after three months of BC therapy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Six-minute walk distance (6MWD) pre-treatment
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Six-minute walk distance (6MWD) post-treatment
Number of subjects: 110

Group type: COMPARATOR
Intervention: Left ventricular ejection fraction (LVEF) pre-treatment
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (LVEF) post-treatment
Number of subjects: 110
Study: 35775319

Group type: EXPERIMENTAL
Intervention: Dupilumab treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35775373

Group type: EXPERIMENTAL
Intervention: Burosumab
Number of subjects: 0
Study: 35775390

Group type: EXPERIMENTAL
Intervention: CD34 cell therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 30
Study: 35775417

Group type: EXPERIMENTAL
Intervention: Neo-Commissural Alignment Technique for Transcatheter Aortic Valve Replacement using the ACURATE Neo Valve
Number of subjects: 0
Study: 35776072

Group type: EXPERIMENTAL
Intervention: Asciminib 40 mg b.i.d.
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Asciminib (various doses from 10 to 200 mg b.i.d. or 40 to 200 mg q.d.)
Number of subjects: 303
Study: 35776131

Group type: EXPERIMENTAL
Intervention: Universal gown and glove use for all patient contact
Number of subjects: 21845

Group type: COMPARATOR
Intervention: Standard practice for glove and gown use (control)
Number of subjects: 21845
Study: 35776144

Group type: EXPERIMENTAL
Intervention: No-stent strategy (SCBA followed by DCB)
Number of subjects: 984

Group type: COMPARATOR
Intervention: Conventional DES
Number of subjects: 984

Group type: COMPARATOR
Intervention: BO-stent
Number of subjects: 984

Group type: COMPARATOR
Intervention: DCB-only
Number of subjects: 984
Study: 35776185

Group type: EXPERIMENTAL
Intervention: Doxycycline 50 mg once daily
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg once daily
Number of subjects: 34
Study: 35776199

Group type: EXPERIMENTAL
Intervention: ET019003 T cells (autologous CD19-directed AbTCR T cells)
Number of subjects: 12
Study: 35776242

Group type: EXPERIMENTAL
Intervention: Regional analgesia (transversus abdominis plane and rectus sheath block)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: External oblique intercostal block
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 113
Study: 35776269

Group type: EXPERIMENTAL
Intervention: SB5-HC (40 mg/0.4 ml)
Number of subjects: 188

Group type: COMPARATOR
Intervention: SB5-LC (40 mg/0.8 ml)
Number of subjects: 188
Study: 35776432

Group type: EXPERIMENTAL
Intervention: USPIO-enhanced MRI
Number of subjects: 10
Study: 35776489

Group type: EXPERIMENTAL
Intervention: Daily meditation via Calm app
Number of subjects: 276

Group type: COMPARATOR
Intervention: Health education podcast control group
Number of subjects: 276
Study: 35776519

Group type: EXPERIMENTAL
Intervention: Neurological Pupil index (NPi) for the right eye
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Neurological Pupil index (NPi) for the left eye
Number of subjects: 43
Study: 35776711

Group type: EXPERIMENTAL
Intervention: Heated saline-enhanced radiofrequency (SERF) needle ablation
Number of subjects: 32
Study: 35776862

Group type: EXPERIMENTAL
Intervention: Omadacycline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Linezolid (Control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moxifloxacin (Control)
Number of subjects: 0
Study: 35776863

Group type: EXPERIMENTAL
Intervention: 8-week telerehabilitation program based on exercises and pain education
Number of subjects: 65

Group type: COMPARATOR
Intervention: Web-based self-management booklet
Number of subjects: 65
Study: 35776909

Group type: EXPERIMENTAL
Intervention: TCR-αβ/CD19-depleted haploidentical HCT
Number of subjects: 51

Group type: COMPARATOR
Intervention: KIR-favorable haploidentical cohort
Number of subjects: 51
Study: 35777109

Group type: EXPERIMENTAL
Intervention: New formula (EF) based on standard formula supplemented with synbiotics, long chain polyunsaturated fatty acids (LC-PUFA) and bovine milk fat globule membranes (MFGM)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: New formula (EF)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Standard formula (SF)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Breastfed reference group (BF)
Number of subjects: 170
Study: 35777186

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg Q3W for up to 35 cycles (∼2 years)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg Q3W
Number of subjects: 109
Study: 35777697

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET) 'check-ups'
Number of subjects: 0
Study: 35778065

Group type: EXPERIMENTAL
Intervention: VICTORI (Virtual Immersive Communication Training on Recommending Immunizations) including VR simulations and a smartphone application.
Number of subjects: 134

Group type: COMPARATOR
Intervention: Smartphone application only (comparison group).
Number of subjects: 134
Study: 35778500

Group type: EXPERIMENTAL
Intervention: Validated anti-AAV6 cell-based transduction inhibition (TI) assay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plate quality control samples
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Donor samples
Number of subjects: 0
Study: 35778519

Group type: EXPERIMENTAL
Intervention: Tattooed skin
Number of subjects: 33

Group type: COMPARATOR
Intervention: Non-tattooed skin
Number of subjects: 33
Study: 35778568

Group type: EXPERIMENTAL
Intervention: Selective agonist of CB2r (JWH133)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antioxidants (from phase II clinical trial NCT01495260)
Number of subjects: 0
Study: 35778636

Group type: EXPERIMENTAL
Intervention: Tislelizumab treatment
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: PD-L1 TAP ≥ 5% and lack of hyperamplification (HA -)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: PD-L1 positivity, IFNγ-related gene signature, TMB-high status
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Hyperamplification (HA +)
Number of subjects: 105
Study: 35778674

Group type: EXPERIMENTAL
Intervention: Chronic pain after cardiac surgery
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Preoperative frailty domains (medication use, living situation, mobility, gait speed, Nagi's physical functioning, preoperative HRQL)
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Chronic pain
Number of subjects: 518
Study: 35778703

Group type: EXPERIMENTAL
Intervention: Sputum supernatant (SPU)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Plasma (PLA)
Number of subjects: 71
Study: 35778757

Group type: EXPERIMENTAL
Intervention: Myoelectric computer interface (MyoCI) training for 6 weeks
Number of subjects: 32
Study: 35778956

Group type: EXPERIMENTAL
Intervention: Airway replacement using stented aortic matrices
Number of subjects: 35
Study: 35779080

Group type: EXPERIMENTAL
Intervention: Surgery for colorectal cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systematic clinical auditing activity
Number of subjects: 0
Study: 35779081

Group type: EXPERIMENTAL
Intervention: Index surgery for traumatic fistulas (iatrogenic and obstetric)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Repeated operations for traumatic fistulas (iatrogenic and obstetric)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Index surgery for inflammatory fistulas (Crohn's disease, cryptoglandular infection, and anastomotic leakage)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Final follow-up for inflammatory fistulas (Crohn's disease, cryptoglandular infection, and anastomotic leakage)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Index surgery for others (radiation damage and unknown etiology)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Final follow-up for others (radiation damage and unknown etiology)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Unhealed patients
Number of subjects: 55
Study: 35779095

Group type: EXPERIMENTAL
Intervention: Polyvalent antigen-KLH plus OPT-821 vaccine construct and bevacizumab
Number of subjects: 21
Study: 35779166

Group type: EXPERIMENTAL
Intervention: Hypoglossal nerve stimulation (HNS)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Positive airway pressure (PAP)
Number of subjects: 227
Study: 35779511

Group type: EXPERIMENTAL
Intervention: Detoxification (3-week inpatient)
Number of subjects: 30
Study: 35779659

Group type: EXPERIMENTAL
Intervention: TXR 140 μg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: TXR 200 μg
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 35779669

Group type: EXPERIMENTAL
Intervention: Caribbean Hispanic/Latinx (CHL)
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Puerto Ricans (PR)
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Cubans/Dominicans (C&D)
Number of subjects: 598
Study: 35780090

Group type: EXPERIMENTAL
Intervention: Primary care physician actions at initial visit for adolescents with suicidal risk
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Reporting of active suicidal ideation, past suicide attempts, referrals to behavioral health counseling, and diagnosis of depression
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Asking about weapons in the home
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Asking about safety plans
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Follow-up for adolescents with a history of suicide concerns
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Need for national guidelines regarding primary care follow-up of youth with suicide concerns
Number of subjects: 200
Study: 35780092

Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion in SOMATO-treated patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion in SOMATO-untreated patients
Number of subjects: 28
Study: 35780095

Group type: EXPERIMENTAL
Intervention: ePRO follow-up pathway with automated 3-monthly reminders for ePRO questionnaire and blood tests.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ePRO follow-up pathway
Number of subjects: 24
Study: 35780200

Group type: EXPERIMENTAL
Intervention: sBAFF
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: sAPRIL
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: sBAFF and sAPRIL correlation
Number of subjects: 100
Study: 35780243

Group type: EXPERIMENTAL
Intervention: Troriluzole (BHV-4157) 420 mg total daily dose in combination with nivolumab 240 mg IV every 2 weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Troriluzole monotherapy (lead-in period)
Number of subjects: 14
Study: 35781099

Group type: EXPERIMENTAL
Intervention: Belumosudil (oral rho-associated coiled-coil-containing protein kinase-2 (ROCK2) inhibitor)
Number of subjects: 170
Study: 35781166

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus lenvatinib (PL)
Number of subjects: 697

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 697
Study: 35781776

Group type: EXPERIMENTAL
Intervention: Stratified medical therapy based on the type of INOCA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive medical therapy
Number of subjects: 0
Study: 35781807

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 80
Study: 35782623

Group type: EXPERIMENTAL
Intervention: Oral lucerastat twice daily for 6 months
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 35782751

Group type: EXPERIMENTAL
Intervention: Paclitaxel (80 mg/m2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regorafenib and paclitaxel
Number of subjects: 0
Study: 35782928

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Number of subjects: 523

Group type: COMPARATOR
Intervention: Low-fat Diet
Number of subjects: 523
Study: 35782954

Group type: EXPERIMENTAL
Intervention: Prebiotic fiber supplement (12 g daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (12 g daily)
Number of subjects: 20
Study: 35783246

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory treatment
Number of subjects: 2008

Group type: EXPERIMENTAL
Intervention: Two subphenotypes identified
Number of subjects: 2008

Group type: EXPERIMENTAL
Intervention: Operative mortality
Number of subjects: 2008

Group type: EXPERIMENTAL
Intervention: Subphenotype frequency
Number of subjects: 2008
Study: 35783610

Group type: EXPERIMENTAL
Intervention: Convalescent plasma therapy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (no convalescent plasma therapy)
Number of subjects: 104
Study: 35783648

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35783649

Group type: EXPERIMENTAL
Intervention: Quality improvement care bundle for the management of acute spontaneous intracerebral hemorrhage (ICH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Care bundle integration into routine care
Number of subjects: 0
Study: 35783686

Group type: EXPERIMENTAL
Intervention: Screening for sexually transmitted infections (STIs) using an in-house polymerase chain reaction panel.
Number of subjects: 148
Study: 35783822

Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg po twice daily for 30 days plus standard of care
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 93
Study: 35783836

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 9 weeks
Number of subjects: 73

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT) for 9 weeks
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 73
Study: 35784017

Group type: EXPERIMENTAL
Intervention: Knee Pain (KP)
Number of subjects: 2832

Group type: EXPERIMENTAL
Intervention: Paracetamol and opioids
Number of subjects: 2832

Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 2832

Group type: COMPARATOR
Intervention: Controls without KP or knee OA
Number of subjects: 2832
Study: 35784538

Group type: EXPERIMENTAL
Intervention: High admission blood glucose (ABG) group
Number of subjects: 6892

Group type: COMPARATOR
Intervention: Low admission blood glucose (ABG) group
Number of subjects: 6892
Study: 35784545

Group type: EXPERIMENTAL
Intervention: Thyroid hormone sensitivity (measured by TSHI, TFQI, TSHI, TT4RI, PTFQI, FT3/FT4)
Number of subjects: 30244

Group type: EXPERIMENTAL
Intervention: Thyroid hormone sensitivity (in females)
Number of subjects: 30244

Group type: EXPERIMENTAL
Intervention: Thyroid hormone sensitivity (in patients aged over 60 years)
Number of subjects: 30244
Study: 35784546

Group type: EXPERIMENTAL
Intervention: Berberine (BBR) alone
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Inulin plus Berberine (BBR)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Inulin alone
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 35784580

Group type: EXPERIMENTAL
Intervention: Decreasing dietary salt intake
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Steadily low dietary salt intake
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Increasing dietary salt intake
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Steadily medium dietary salt intake
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Steadily high dietary salt intake
Number of subjects: 1090
Study: 35784641

Group type: EXPERIMENTAL
Intervention: Adipose-derived MSC infusions (1 × 10)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10
Study: 35785107

Group type: EXPERIMENTAL
Intervention: Transcervical fibroid ablation (TFA) with the Sonata System
Number of subjects: 28
Study: 35785613

Group type: EXPERIMENTAL
Intervention: Peer support services integrated into primary care for OUD treatment.
Number of subjects: 2700000

Group type: COMPARATOR
Intervention: Buprenorphine treatment for OUD.
Number of subjects: 2700000
Study: 35785621

Group type: EXPERIMENTAL
Intervention: Dabigatran, Rivaroxaban, Apixaban (DOACs)
Number of subjects: 478
Study: 35786528

Group type: EXPERIMENTAL
Intervention: Baricitinib (janus kinase inhibitor)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Not applicable (pre-treatment values)
Number of subjects: 142
Study: 35786544

Group type: EXPERIMENTAL
Intervention: Deep neural network (DNN) using accelerometry (ACC) and photoplethysmography (PPG) signals
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Deep neural network (DNN) using wrist-worn CST data
Number of subjects: 301

Group type: COMPARATOR
Intervention: Spectral preprocessing
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Combination of ACC and PPG modalities
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Increasing input segment size to 1024 epochs (∼8.5 hrs.)
Number of subjects: 301
Study: 35786738

Group type: EXPERIMENTAL
Intervention: Biliary stenting
Number of subjects: 211

Group type: COMPARATOR
Intervention: T-tube drainage
Number of subjects: 211

Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 211
Study: 35786777

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) using Dexcom G6 device
Number of subjects: 10

Group type: COMPARATOR
Intervention: Matched healthy volunteers
Number of subjects: 10
Study: 35787017

Group type: EXPERIMENTAL
Intervention: Bone marrow biopsies (BMB) before/after therapy
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Bone marrow biopsies (BMB)
Number of subjects: 580
Study: 35787273

Group type: EXPERIMENTAL
Intervention: PREVENT intervention sites
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 158
Study: 35787726

Group type: EXPERIMENTAL
Intervention: ICU admission
Number of subjects: 4041
Study: 35787784

Group type: EXPERIMENTAL
Intervention: PI3Kα inhibitor alpelisib
Number of subjects: 0